Mesenchymal Stromal Cells to Modulate Immune Reconstitution Early Post-hematopoietic Cell Transplantation

Overview

Journal BMC Immunol

Publisher Biomed Central

Specialty Allergy & Immunology

Date 2015 Dec 18

PMID 26674007

Citations 5

Authors

Elizabeth O Stenger

Lakshmanan Krishnamurti

Jacques Galipeau

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution, promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD). Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety of animal models. Clinical trials have been small and largely non-randomized but have established safety and early evidence of efficacy, supporting the need for larger randomized trials.

Citing Articles

Cell Therapy as a Way to Increase the Effectiveness of Hematopoietic Stem Cell Transplantation.

Pashkina E, Blinova E, Bykova M, Aktanova A, Denisova V Cells. 2025; 13(24.

PMID: 39768148 PMC: 11675046. DOI: 10.3390/cells13242056.

Assessment of the Effect of Infliximab on Immunomodulation Properties of Mesenchymal Stem Cells .

Sakha Y, Ehsani E, Roshandel E, Jalili A, Vahdani N, Hajifathali A Adv Pharm Bull. 2021; 11(4):739-745.

PMID: 34888221 PMC: 8642797. DOI: 10.34172/apb.2021.083.

Use of MSCs and MSC-educated macrophages to mitigate hematopoietic acute radiation syndrome.

Chinnadurai R, Forsberg M, Kink J, Hematti P, Capitini C Curr Stem Cell Rep. 2020; 6(3):77-85.

PMID: 32944493 PMC: 7491866. DOI: 10.1007/s40778-020-00176-0.

Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study.

Boberg E, Von Bahr L, Afram G, Lindstrom C, Ljungman P, Heldring N Stem Cells Transl Med. 2020; 9(10):1190-1202.

PMID: 32573983 PMC: 7519760. DOI: 10.1002/sctm.20-0099.

Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology.

Perico N, Casiraghi F, Remuzzi G J Am Soc Nephrol. 2017; 29(2):362-375.

PMID: 29191959 PMC: 5791082. DOI: 10.1681/ASN.2017070781.

References

MacMillan M, Blazar B, DeFor T, Wagner J . Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2008; 43(6):447-54. DOI: 10.1038/bmt.2008.348. View

Mielcarek M, Storb R, Georges G, Golubev L, Nikitine A, Hwang B . Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010; 17(2):214-25. PMC: 3026853. DOI: 10.1016/j.bbmt.2010.08.015. View

Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L . Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood. 2004; 103(9):3313-9. DOI: 10.1182/blood-2003-04-1121. View

Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D . Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004; 103(12):4619-21. DOI: 10.1182/blood-2003-11-3909. View

Le Blanc K, Mougiakakos D . Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012; 12(5):383-96. DOI: 10.1038/nri3209. View

In t Anker P, Noort W, Scherjon S, Kleijburg-van der Keur C, Kruisselbrink A, van Bezooijen R . Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. 2003; 88(8):845-52. View

Aggarwal S, Pittenger M . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2004; 105(4):1815-22. DOI: 10.1182/blood-2004-04-1559. View

Francois M, Romieu-Mourez R, Li M, Galipeau J . Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2011; 20(1):187-95. DOI: 10.1038/mt.2011.189. View

Su J, Chen X, Huang Y, Li W, Li J, Cao K . Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 2013; 21(3):388-96. PMC: 3921585. DOI: 10.1038/cdd.2013.149. View

10.

Liu H, Sun Z, Geng L, Wang X, Ding K, Tang B . Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant. 2012; 47(9):1186-90. DOI: 10.1038/bmt.2011.251. View

11.

Nauta A, Westerhuis G, Kruisselbrink A, Lurvink E, Willemze R, Fibbe W . Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006; 108(6):2114-20. PMC: 1895546. DOI: 10.1182/blood-2005-11-011650. View

12.

Bernardo M, Cometa A, Locatelli F . Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?. Bone Marrow Transplant. 2011; 47(3):323-9. DOI: 10.1038/bmt.2011.102. View

13.

Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S . CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010; 95(4):651-9. PMC: 2857196. DOI: 10.3324/haematol.2009.015065. View

14.

de Lima M, McNiece I, Robinson S, Munsell M, Eapen M, Horowitz M . Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012; 367(24):2305-15. PMC: 3805360. DOI: 10.1056/NEJMoa1207285. View

15.

Bernardo M, Ball L, Cometa A, Roelofs H, Zecca M, Avanzini M . Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2010; 46(2):200-7. DOI: 10.1038/bmt.2010.87. View

16.

Lazarus H, Koc O, Devine S, Curtin P, Maziarz R, Holland H . Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005; 11(5):389-98. DOI: 10.1016/j.bbmt.2005.02.001. View

17.

Kebriaei P, Robinson S . Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy. 2011; 13(3):262-8. DOI: 10.3109/14653249.2010.549688. View

18.

Mattsson J, Ringden O, Storb R . Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14(1 Suppl 1):165-70. PMC: 2344125. DOI: 10.1016/j.bbmt.2007.10.025. View

19.

Almeida-Porada G, Porada C, Tran N, Zanjani E . Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood. 2000; 95(11):3620-7. View

20.

Francois M, Copland I, Yuan S, Romieu-Mourez R, Waller E, Galipeau J . Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy. 2011; 14(2):147-52. PMC: 3279133. DOI: 10.3109/14653249.2011.623691. View